A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Clinical trials for prophylactic human papillomavirus (HPV) vaccines have shown overwhelmingly positive results. It is expected that with good coverage of the vaccine, 70% of cervical cancers will be prevented, as will a proportion of other HPV-related anogenital diseases. Issues that will require careful consideration will include: whether males and females should be vaccinated; the durability of the immune response; the proportion of attributable disease to the HPV types targetted by thedoi:10.1071/sh06018 pmid:16800389 fatcat:hmeickjjendqhj7hktopiq2i5e